↓ Skip to main content

Dove Medical Press

Article Metrics

OnabotulinumtoxinA for chronic migraine: a critical appraisal

Overview of attention for article published in Therapeutics and Clinical Risk Management, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#33 of 922)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
twitter
4 tweeters

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
24 Mendeley
Title
OnabotulinumtoxinA for chronic migraine: a critical appraisal
Published in
Therapeutics and Clinical Risk Management, June 2015
DOI 10.2147/tcrm.s76964
Pubmed ID
Authors

Fayyaz Ahmed, Rubesh Gooriah

Abstract

Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its benefits and potential use in migraine were observed incidentally while treating patients cosmetically for wrinkles. The mechanism of action of onaBoNTA in CM is not fully understood, but there is evidence that this involves axonal transport via sensory fibers. The Phase III REsearch Evaluating Migraine Prophylaxis Therapy trials have established the efficacy as well as the long-term safety and tolerability of onaBoNTA in CM. This review will discuss the evidence behind its use in this setting.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 4%
Unknown 23 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 25%
Student > Bachelor 5 21%
Student > Ph. D. Student 3 13%
Professor 2 8%
Researcher 2 8%
Other 3 13%
Unknown 3 13%
Readers by discipline Count As %
Medicine and Dentistry 12 50%
Nursing and Health Professions 3 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Neuroscience 2 8%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 0 0%
Unknown 4 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2017.
All research outputs
#966,899
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#33
of 922 outputs
Outputs of similar age
#23,955
of 234,264 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 56 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,264 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.